

NEWS FROM S·P·O·H·N·C



VOL. 30 NO. 6

SUPPORT FOR PEOPLE WITH ORAL AND HEAD AND NECK CANCER, INC.

APRIL 2021



Cell Free HPV DNA: A new diagnostic and predictive test for HPV oropharynx cancer

Marshall Posner, MD &
Eric Genden, MD, MHCA, FACS

A large shift in the causes and natural history of head and neck cancer has radically changed the prognosis and survival of a significant fraction of patients in the last two decades. This has been driven by the identification of human papilloma virus (HPV) as the major causative factor in oropharynx cancer (OPC). HPV-related OPC is now so common and the biology and prognosis are so different from environmentally and smoking



related head and neck cancers that it has a specific designation - HPVOPC. HPV is a transmissible virus which is passed among people by exchange of bodily fluids usually associated with sexual activity. Living virus does not enter into the blood stream and cannot be transmitted by blood transfusion or exposure. Many people are infected in their teenage years or in young

adulthood by sexual or intimate acts that transmit bodily fluids. The virus is highly infectious and is likely transmitted by kissing or exchange of saliva in teenagers and adults. Fortunately, the development of an HPV vaccine may reduce the incidence of this cancer. The impact of preventative HPV vaccines on later cancer development will not be realized for about 30 more years as the vaccinated population matures. While HPV infection is nearly ubiquitous, very few people develop an HPV-related cancer. In fact, the vast majority of those infected will not develop HPV-associated malignancy

April is Oral, Head and Neck Cancer Awareness Month

*This issue of
"News from SPOHNC"
is dedicated to
SPOHNC's Founder,
Nancy Leupold,
in memoriam...*



and may asymptotically carry the virus. Nonetheless, HPV-associated OPC now represents about 60-70% of all head and neck oropharynx cancer seen in the United States and it is expected that there will be more than 30,000 cases a year by 2025. We have also found that HPV is implicated in significant fraction of sinus cancers and a small fraction of nasopharynx cancers. Outside of the head and neck HPV is associated with anal, cervical, vulvar, and penile cancers.

Unlike tobacco-related head and neck cancer, HPV OPC is very responsive to radiation or chemotherapy and cure rates for patients range between 65% and 95% - as opposed to 30-45% for tobacco-related head and neck cancer. While biomarkers such as invasion of blood vessels, nerves, and lymphatics are considered poor prognostic factors in tobacco-related disease, these biomarkers are less indicative of a poor outcome in HPV-associated cancer. These findings support that HPV-associated disease is fundamentally different than tobacco-associated disease.



Because cure rates are high in HPV associated oropharyngeal cancer, more emphasis has been placed on treatment toxicity. This is especially important because, in general, the patients develop this disease at a younger age than patients afflicted with tobacco associated disease.

They will survive for decades after treatment. The long-term consequences of therapy have become an important consideration in this population of patients. Therefore, the goal of reducing aggressive therapy and thus the significant late toxic effects of chemo-radiation and surgery have to enter into the equation of management and decision making. Radiation carries the greatest burden of acute toxicity effects and significant long-term consequential toxicity. Reducing the dose of radiation, while preserving high survival rates would have a significant impact on quality of life in this highly curable disease. Additionally,

HPV DNA continued on page 2

Make a Difference. Give a Gift Today.



Nancy E. Leupold, MA
In Memoriam

BOARD OF DIRECTORS

James J. Sciubba, DMD, PhD, President
Walter E. Boehmler, Treasurer
Gail Fass, Secretary
Dorothy Gold, MSW, LCSW-C, OSW-C
Eugene N. Myers, MD, FACS, FRCS, Edin (Hon)

EXECUTIVE DIRECTOR

Mary Ann Caputo

MEDICAL ADVISORY BOARD

David M. Brizel, MD <i>Duke University Medical Center</i>	Kristen B. Pytynia, MD, MPH <i>MD Anderson Cancer Center</i>
Allen M. Chen, MD <i>University of California, Irvine</i>	Karrie Zampini Robinson, LCSW <i>Fighting Chance</i>
David W. Eisele, MD, FACS <i>Johns Hopkins Univ. School of Medicine</i>	David L. Schwartz, MD <i>The Univ. of Tennessee Hlth. Sci. Ctr.</i>
Robert Ferris, MD, PhD, FACS <i>University of Pittsburgh</i>	James J. Sciubba, DMD, PhD <i>Greater Baltimore Medical Center</i>
Bonnie Martin-Harris, PhD, CCC-SLP <i>Northwestern University</i>	Elliot W. Strong, MD, FACS, Emeritus <i>Memorial Sloan-Kettering Cancer Center</i>
David Myssiorek, MD, FACS <i>BronxCare Center</i>	Everett E. Vokes, MD <i>University of Chicago Medical Center</i>
David G. Pfister, MD <i>Memorial Sloan-Kettering Cancer Center</i>	Randal S. Weber, MD, FACS <i>MD Anderson Cancer Center</i>
Jed Pollack, MD <i>Northwell Health</i>	Dan Zandberg, MD <i>University of Pittsburgh</i>

NEWSLETTER EDITOR

Chris Leonardis

News From SPOHNC is a publication of
Support for People with Oral and Head and Neck Cancer, Inc.
Copyright ©2020-2021

DISCLAIMER: Support for People with Oral and Head and Neck Cancer, Inc. does not endorse any treatments or products mentioned in this newsletter. Please consult your physician before using any treatments or products.

IN THIS ISSUE

Medical Advisory Board News.....4,5
Partnership/Contribution Acknowledgements.....6,7,8
Nancy Leupold's Loving Page of Remembrance.....9, 10



HPV DNA continued from page 1

surveillance and follow-up are critically important to identify recurrent disease early in the process so that salvage treatment can be instituted. There is a need to develop better diagnostic and prognostic tests that are accurate and cost effective. With increasing numbers of survivors, there is an increasing need for noninvasive surveillance. Positron emission tomography (PET) scan is one of the best diagnostic tests available for this disease. Unfortunately, it is costly and is associated with a relative high radiation dose compared to other radiologic methods and may be associated with unexpected toxicity and consequences over time. Nonetheless, finding recurrences or identifying persistent disease early after initial treatment can lead to successful salvage treatments. As more patients achieve cure, surveillance testing becomes increasingly necessary and expensive. Second, a pre-therapy prognostic test that identifies patients who will most likely achieve cure with a reduced dose of radiotherapy or chemotherapy would help to facilitate risk based reduction in these treatments. Reducing primary treatment, especially radiation therapy, will improve long-term consequences and morbidity as well as improve survival for patients. Third, a post radiation or postoperative test that accurately identified patients who need more therapy because of persistence or residual disease would allow early intervention with additional therapies including vaccines and immune modulators. Evaluation of patients in the immediate postoperative or post radiation setting is very complicated by tissue inflammation and swelling. Having a highly sensitive or specific test would improve identification of persistent disease where additional treatment may be beneficial.

Recently, a new test has been developed which has some characteristics that would appear to meet some or all of these needs. This biomarker test is based on the fact that in HPV OPC, human papilloma virus is present in all HPV OPC tumors and that measuring virus in blood may serve as a highly specific biomarker of HPV cancer. Because the virus is necessary for the tumors to maintain a malignant state it is both a target for therapy and a diagnostic biomarker test for the cancer and for prognosis. It has now been shown by academic laboratories (Dana Farber Cancer Institute; Mount Sinai Medical Center; Johns Hopkins University School of Medicine; Case Western Reserve; MD Anderson Cancer Center; University of North Carolina) that it is possible to detect cell free fragments of HPV viral DNA in the blood of patients who have active HPV OPC¹⁻⁶. There is also at least 1 commercial entity (Naveris) which provides commercial clinical testing. This test is in the early stages of development and the technology is relatively expensive and not routinely available. It is, however, very promising. The concept makes good rational sense and is currently being investigated to see if the promise of a specific and usable plasma test can be realized. We now know that cell free HPV DNA (cfHPVDNA) as a blood test is highly specific to HPV caused cancers. Thus, it may be an excellent test to screen patients who might be at high risk for developing a cancer, predict who might do well with surgery, chemotherapy or radiation and identify recurrences in patients who have been treated for cure and who are in surveillance.

Several studies have shown that the detection of cfHPVDNA can predict recurrence in patients with HPVOPC who have been treated for cure after surgery and chemoradiotherapy. These results are very promising although preliminary. In one study 100% of HPV DNA continued on page 3

HPV DNA continued from page 2

recurrences were identified by a first-time positive test. Many of those patients were initially negative after curative therapy and became positive during repeated testing in follow up. A large fraction of patients, 43%, had an initial false-positive that on repeat testing became negative and only 6% with 2 positive tests did not have recurrence identified. However, the remaining patients, all with 2 positive tests (94%), were found to have a recurrence². These early results are very exciting. There are many details that have to be worked out for physicians to know how to use cfHPVDNA and for routine testing to become a standard of care⁶. One clear conclusion from the data is that many patients were negative after definitive treatment and then developed a positive test indicating that there is a minimum volume threshold necessary to identify persistent or recurrent disease. This leads to a number of questions on how to utilize the test: for example, how often to do testing. Should it be every month for the first 6 months or year after surgery or radiation therapy or perhaps only in the first 6 months and then quarterly after that? How truly sensitive and accurate is the test? Does this become a confirmatory test for a positive scan or the primary diagnostic test? Are we finding tumors early enough in recurrence and how much of a threshold of volume is necessary to be positive – and might they be found by physical exam or appear on PET scans earlier when they are still small and below a cfHPVDNA threshold? There may not

be a direct correlation of cfHPVDNA to volume. The biology of each cancer in each person might be unique and might impact on the sensitivity of the assay to recurrence. A positive cfHPVDNA does not tell the physician if this is a local or metastatic spread. This may confound decisions about regional versus systemic salvage treatment. Finally, in our unpublished experience we found that some HPVOPC patients developed late second cancers that were HPV negative and may have been secondary to life style causes such as smoking or to prior radiation therapy. These second cancers can be shown to be molecularly distinct and not HPV related by molecular diagnostic studies. These latter events support lifelong follow-up in patients who smoked or were treated with radiation.

One potential use of the test would be to select patients after surgery who would benefit from postoperative radiotherapy or immunotherapy. This testing could take place in the 6 week window in which postoperative chemoradiotherapy is optimally started. It might also be possible for those patients getting primary chemoradiotherapy to do a midcourse test and evaluate whether they are having a sufficient response such that more or less radiation would be indicated. Pretreatment testing will also be important. There is some very preliminary data that suggests lower levels of cfHPVDNA fragments prior to therapy may be predictive of a poor prognosis biology and early recurrence although this is not consistent⁶.

It is possible that molecular characteristics of the fragments might give information on the prognosis as well. These changes could suggest a more resistant form of HPV in the cancers. In patients with locally advanced disease who receive chemotherapy prior to chemoradiotherapy or primary chemo radiotherapy evaluating the velocity of decrease - the rate at which the levels of cfHPVDNA decrease or if they reach 0 during therapy- might help select patients for even further reductions in chemoradiation therapy.

Many of these questions have not been addressed as of yet. However, this is a very exciting new technology which holds great promise for helping improve the outcome in patients. Getting sufficient data through clinical trials to optimally use this test will take some time. However, as our understanding and utilization of the test unfold we will hopefully be able to apply it to improve the quality of life, cost of treatment, treatment toxicity, and anxiety of our patients.

Selected Bibliography:

1. Chera BS, Kumar S, Beatty BT, et al: Rapid Clearance Profile of Plasma Circulating Tumor HPV Type 16 DNA during Chemoradiotherapy Correlates with Disease Control in HPV-Associated Oropharyngeal Cancer. *Clin Cancer Res* 25:4682-4690, 2019
2. Chera BS, Kumar S, Shen C, et al: Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer. *J Clin Oncol*:JCO1902444, 2020
3. Hanna GJ, Supplee JG, Kuang Y, et al: Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer. *Ann Oncol* 29:1980-1986, 2018
4. Dahlstrom KR, Li G, Hussey CS, et al: Circulating human papillomavirus DNA as a marker for disease extent and recurrence among patients with oropharyngeal cancer. *Cancer* 121:3455-64, 2015
5. Wang Y, Springer S, Mulvey CL, et al: Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. *Sci Transl Med* 7:293ra104, 2015
6. Chatfield-Reed K, Roche VP, Pan Q: cfDNA detection for HPV+ squamous cell carcinomas. *Oral Oncol* 115:104958, 2021

HPV DNA continued on page 4

Your Cancer Story... Real Letters. Real People.

As Merck and SPOHNC continue their partnership, which began with *Your Cancer Game Plan*, and continued with the *With Love, Me* campaign we are excited and proud to present to you...*Your Cancer Story*...the latest initiative of this program designed to share help, and hope, with those who have been affected by the diagnosis and treatment of oral, head and neck cancer.

“Just do your best – whatever that means in the moment.” Julia, a cancer survivor, shares impactful advice about what she wishes she’d known at the start of her #cancer journey. Hear from others by visiting @Merck’s Your Cancer Story. #MerckPartner



Make a Difference. Give a Gift Today.

HPV DNA continued from page 3

Editors Note: Dr. Marshall Posner is Professor of Medicine Icahn School of Medicine at Mount Sinai, NY. He is Medical Director of the Head and Neck Oncology Program, Associate Director of the Center for Personalized Cancer Therapeutics, and co-Director of the Cancer Clinical Investigation Program for the Tisch Cancer Institute. Dr. Posner has published over 275 peer-reviewed laboratory and clinical studies. He has been principal investigator of NIH grants in immunology and has been principal investigator of multiple Phase 1, 2 and 3 clinical trials. He has a strong clinical and clinical research focus on Immunotherapy, HPV oropharynx cancer and salivary gland cancers.

Dr. Eric Genden is a member of

the Icahn School of Medicine at Mount Sinai faculty since 1988. Dr. Genden is an internationally recognized expert and innovator in the management of head and neck cancer; microvascular reconstruction of the head and neck, and transplantation. He is the Dr. Isidore Friesner Endowed Professor and System Chairman of the Department of Otolaryngology – Head and Neck Surgery and a Professor of Neurosurgery and Immunology. His many leadership roles at Mount Sinai include Senior Associate Dean for Clinical Affairs at the Icahn School of Medicine at Mount Sinai. Dr. Genden plays a leadership role with the Mount Sinai Doctors Faculty Practice and he is a Senior Vice-President for Ambulatory Surgery Development.



Medical Advisory Board News

SPOHNC is pleased to announce that Robert Ferris, MD, PhD, FACS has accepted our invitation to serve as a member of



our Medical Advisory Board. Dr. Ferris is a world renowned head and neck cancer physician, and SPOHNC is honored and grateful for his acceptance of this position.

Robert L. Ferris, MD, PhD is Hillman Professor of Oncology and Director, UPMC Hillman Cancer Center and Co-Director of the Tumor Microenvironment Center. Since 2007 he was Co-Leader of the Cancer Immunology Program and Associate Director for Translational Research at the University of Pittsburgh Cancer Institute (UPCI). Dr. Ferris received his medical and graduate training in Immunology at Johns Hopkins, then completed his residency and subspecialty training in head and neck surgical oncology in 2001. In 2006, he received the Excellence in Clinical

Investigations award at UPCI and was elected to the American Society for Clinical Investigation (ASCI) in 2008.

Dr. Ferris has also been active in the Society for the Immunotherapy of Cancer (SITC) for 15 years. He is also a Section Editor of the *Journal of Immunotherapy of Cancer* (JITC) and serves on the Editorial Boards of the *Journal of Clinical Oncology*, *Clinical Cancer Research* and *Cancer Immunology Research* and as Associate Editor for *JNCI*.

Dr. Ferris' research interests include Cancer Immunotherapy, TransOral Robotic Head and Neck, Surgery Video Assisted, Thyroid/Parathyroid Surgery, Cybernife/ Stereotactic Radiosurgery, Endoscopic Partial Laryngectomy.

Dr. Ferris has been a good friend to SPOHNC for many years, authoring articles for "News from SPOHNC" and sharing his expertise with our audience on several webinars and at conferences as well.

We welcome Dr. Ferris, and SPOHNC appreciates his unwavering commitment to those who have been affected by the diagnosis and treatment of oral, head and neck cancer.



Become a SPOHNC member today and receive all 8 issues of this newsletter and our Product Directory.

Here's what people are saying about becoming a SPOHNC member:

"To read your October issue of "News from SPOHNC" reminded me of what a great organization I have been a member of for the past 17 years."


~ Philip LoPresti, MD

"Wow! Just took a look at the Product Directory! You did a great job. Thank you."

~ Jon T.

**CALL SPOHNC TODAY TO JOIN US!
1-800-377-0928
or go to spohnc.org**

Do you have a topic of interest that you'd like to see covered in a future feature article in "News from SPOHNC"?



Email us to today at info@spohnc.org We want to hear from you!

Medical Advisory Board News

SPOHNC is pleased to welcome Dan P. Zandberg, MD, to our Medical Advisory Board.

Dr. Zandberg is the Director of the Head and Neck and Thyroid Cancer Disease Sections, Division of Hematology/Oncology and Medical Oncology, and Co-Leader of the UPMC Hillman Head and Neck Cancer Program. He is also the Physician Lead for the second floor Hillman Cancer Center Clinic and an Associate Professor of Medicine.

His main research focus is in the development of clinical trials with immunotherapy to improve patient outcomes. His recent awards include the



2019 National Cancer Institute (NCI) Cancer Clinical Investigator Team Leadership Award, 2020 Leo Crippe, M.D. Excellence in Patient Care Award, and 2020/2021 Castle Connolly Regional Top Doctor.

Dr. Zandberg has been a friend to SPOHNC for several years, authoring a feature article for "News from SPOHNC" in 2018, and most recently, speaking on a webinar co-presented by SPOHNC, entitled *Exploring Clinical Trials in Head and Neck Cancer*.

Thank you, Dr. Zandberg, for your consideration of our request. We look forward to a long and continuing relationship.

"We all need hope and to know there are others like us. It may not be an easy path all the time but we can certainly do it. Just knowing we're not alone is a huge help."



~ Pat L.

SPOHNC's Resources

SPOHNC's most popular resource for newly diagnosed patients is now available as a digital edition!



We Have Walked In Your Shoes: A Guide to Living With Oral, Head and Neck Cancer - by Nancy E. Leupold & James J. Sciubba, DMD, PhD

DIGITAL EDITION Available NOW!

To purchase this welcoming resource in a digital format, go to spohnc.org, and order online. You will receive a link to download the book. Save space on your bookshelf and purchase this digital edition today for \$7.99.

Still want to hold the book in your hands? ***We Have Walked in Your Shoes*** is still available in print.

\$14.95 includes shipping and handling. ***For Bulk order Discount Pricing contact SPOHNC at 1-800-377-0928 or email us at info@spohnc.org***



ROMAN: A study to investigate the effects of GC4419 on **radiation induced oral mucositis** in patients with **Head/Neck Cancer**

www.clinicaltrials.gov

2020



2020

Support for People with Oral and Head and Neck Cancer, Inc. is grateful for the generosity of its contributors. Thanks to their support, SPOHNC is able to maintain and extend its programs of education and support to cancer survivors, their families and friends. With sincere appreciation to all.

CORPORATE PARTNERS

**Bristol-Myers Squibb
CEL-SCI Corporation**

**MeiraGTx
Merck**

**Nanobiotix
SQZ Biotech**

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

CEL-SCI Corporation is involved in the research and development of immunotherapy products for the treatment of cancer, autoimmune and infectious diseases.

MeiraGTx is a clinical-stage gene therapy company focused on developing potentially curative treatments for patients living with serious diseases.

Merck discovers, develops and provides innovative products and services that save and improve lives around the world.

Nanobiotix designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer.

SQZ Biotech is a clinical stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases and other serious conditions

LEADERS CIRCLE

Contributions of \$10,000+

The Leupold Family

SPOHNC Palm Coast, FL Chapter Move to Music Fundraiser

BENEFACTORS

Contributions of \$1,000+

ANONYMOUS

Chuck & Jody Bartlett
Walter & Irene Boehmler
Cancer Support Community
Brandon & Nicole Ewing
Raymond D. Gambale

Diane Huston
Kansas City, KS SPOHNC Chapter
Taste Event
Donald & Mary Leach
Susan Minkowitz
Network for Good

David & Leslie Noble
James Prange
Linda Swalling
Mr. & Mrs. Borden Taylor
Steven Tracy
Ronald & Sandra Walker

PATRONS

Contributions of \$500+

Charles Banta
Roberta Davis
Jack & Temple Igleburger
Neil Johnson

Robert Kreps
Network For Good
Douglas E. Simms
Pastor Sarah Stobie

Scott A. Stone
Daniel M. Tanenbaum
Jon Thibo
Andrew M. Vinciguerra

SPONSORS

Contributions of \$100+

Edna Angeli
Becky Weber
Donald A. Azar
Gerald M. Berger
Ralph Bloom III
Nancy & Ben Boyum
Karen Bunnell
Rita Burfitt
Bruce Burnside
Judi G. Burten-Soll
CAF America
John Casale
Jean O. Cashin

Cynthia Clark
Bill & Linda Clyne
John G. Conover
William D'Anza
Kent E. Davis
James Denton
Denise M. DeSimone
Terence Dowd
Robin Mirvis Eatman
Alan Evans
Linda Farr
Burt & Noelle Faure
Al & Ginny Ferrara

John Fredlund
Lewis R. Gainfort
Frank L. Giancola
John Goldberg
Paul Gough
Thomas W. Gray
Gale Harvey
Ron Harwick
Walter Hoff
Joseph A. Hyland Sr.
Mary Anne Ingram
Karen L. Isaacs
Gail James

SPONSORS continued on next page

S.P.O.H.N.C

P.O. Box 53

Locust Valley, NY 11560-0053

1-800-377-0928

SPONSORS continued from previous page

Tom Jewell
Jill Jones
Daniel Karakla
Jeffrey Kovner
Kim Kucik
David Lowenstein
Roy Marshall
Bonnie Martin-Harris, PhD, CCC-SLP
Barbara McCarty
Catherine McGeachie
Michael McKinnis
Edwin N. Merrell
Roy Miles
Gene Monahan

Virginia Monson
Larry Myers
Network for Good
Sherry B. Niepp
J. Wray Pearce
Christophe Poirier
Charles Raab
Michael Scaperotta
Kurt Schwabe
Ted Seglem
Gale Simmons
Sheila A. Studint
Roger P. Tardie
William C. Temple Jr.

The Gail J. Reynolds Revocable Trust
The Guide Foundation
Glen Thomas
Charlie Tracy
Anna Vallotton
Bill VanHorn
Wayne Vosburgh
Frederick W. Wackerle
Vita A. Waite
Becky Weber
Scott Wieskamp
Patricia Zaharko
Rose Zigenfus

Matthew T. Baker
Helen Beamon
Becker Capital Management, Inc.
Michael Beckerman, MD
Jim Bellinghausen
Gerald M. Berger
Janis J. Borkowski
Jerry Brewer
Bruce E. Brockstein, MD
Curt Brown
Charles Carroll
Connie Cocozzo
Martin D. Cole
John G. Comber
Patrick A. Day
Salvatore P. & Jean Diana
Andrea M. Donelan
Rebecca S. Dresser
Thomas Eich
Andrew Erman, CCC-SLP

DONORS
Contributions of \$50 +
Tim Euler
Greg J. Fix
Richard J. Gillis
Raymond & Marilyn Goodall
Paul Gough
Domenick Grassi
Jeffrey D. Hill
Harold Holady
John M. Holland, MD
Ted Hyslop
Bretton P. Jenks
Gary L. Johnson
Mike Klaassen
Victoria Kuchinski
Linda R. Lane
Linda Martin
Robert J. McAuliffe
Thomas McCammon
Ellen Merrigan
Anthony Montalbano

Tetsuo Najita
Cathy B. Nazeer
Claire C. Nelson
Nancy Newman
Harlan & Pamela Niehaus
Arthur Perlman
George & Dana Reeder
Richard P. Schulman
Geoffrey Sherwood
Howard Strauss, DDS
Candace Tagliavento
Joseph Troy
Raphael G. Urciolo, Jr.
James Vogt
James Wheeler
Diane E. Williams
Steve Wilson
Nyla Wright
Thomas K. Yoder
Andrew Zangara



Trial Sponsor
SQZ Biotechnologies

PHYSICIANS & PATIENTS:
SQZ Biotechnologies (SQZ) is currently enrolling patients in its investigational cell-based Phase 1, multi-center study of SQZ-PBMC-HPV¹ for select cancers; including Head and Neck Cancer.

Eligible patients must meet certain criteria including:

- Male or female patients 18 years of age or older who are HLA-A*02
 - Histologically confirmed incurable or metastatic solid tumors that are HPV16+
 - Cancer must have progressed after at least 1 available standard therapy for incurable disease, or the patient is intolerant to or refuses standard therapy(ies) or has a tumor for which no standard therapy(ies) exist
 - Ability to undergo a leukapheresis 1 to 2 weeks prior to the start of the study treatment. (A leukapheresis is a blood filtration through a machine which collects white blood cells from the blood and then returns everything else back into the bloodstream. Leukapheresis is similar to donating blood and takes about 4 hours.)
- More information about this study, including a list of available clinical trial sites, is available for patients or physicians at <https://clinicaltrials.gov/ct2/show/NCT04084951>**

¹About SQZ-PBMC-HPV
SQZ-PBMC-HPV is an investigational autologous cell therapy product candidate engineered to target HPV+ cancers. It has not been approved for any indication by the Food and Drug Administration (FDA) or any other regulatory agency. The safety and efficacy of this therapy has not been determined.

BOOSTER

Contributions of \$35 +

Rebecca Acosta
Barbara Appel
Linda A. Bardekoff
Cynthia Basile
Jim Bellinghausen
Nicholas Biase
J. Lawrie Bloom
Christian S. Bone
Charles Bonini
Joana Breckner
John Callahan
Linda Calvey
Joan Canty
Lin Casteel-Butler
Donna Clarke
Harriet Dembe
Samuel DiGiacomo
Salvatore DiPasquale
Melvin W. Edgerley
Terence Lee English
Jean Feipel
Michelle Felling
Robert & Fran Fontane

James B. Gaddy, MD
Patrick Gangitano
Keith Gardiner
Patricia Gawron
Katherine Hampton
Patricia Lynn Houck
Bettye Laurena Hutto-Taylor
Sarah S. Hymowitz
Gail James
John L. Jenkins
Bretton P. Jenks
Rev. Paul Jung
Carol Keane
Charles A. Knolls
Les Loth
Michael Maberry
Paul Maidel
Michael Manguso
Donna J. Martin
Valerie Maxwell
Randy Mayor
Jerry Milliken

Taniya Mollah
Sherry B. Niepp
Linda Powell
Constance Rode Craig
Susan Rosenthal Jay
Michelle A. Ryan
Caroline M. Saylor
Linda F. Seiden
Lee A. Stranburg
Robert Sulkis
Nancy Tedesco
James Thiede
Robert Thomas
Deborah Tingen
Sue Tyson
Deborah Ward
Joseph M. Waronka
Diane Wasserman
Kim Webster
Donald C. Weightman
Mary C. Wiak
Loretta Williamson
Tim Zemens

Gifts Have Been Given to SPOHNC In Honor Of

All Head and Neck Cancer Patients by
Craig Bobseine

Bradford Harris Amato by
Dr. John Amato

SPOHNC's Executive Director,
Mary Ann Caputo by
Lawrence Caputo & Family,
John & Roseann Celauro,
Lawrence & Gina DiGiovanna,
Gail Fass, Al & Ginny Ferrara,
Ilene Frischer,
Dr. Eugene & Barbara Myers,
James Sciubba, DMD, PhD,

James Cerreta by David Liscinsky

Harold Clark by Suzanne Berkhofer

Susan Conner by Jody Conner

John & Elaine Couri & Carl Reimerdes
by Alfred & Susan Carfora

Henry Deneski by
Henry and Lilian Deneski

Dr. Daniel Deschler by
Heather Hohenthal

Sandra Knipe by John & Rita Lamont

Ms. Krackstedt by Margaret Frick
Cecelia Luna by Francesca Luna

Kathy Meherin by Sherry Vrooman

Dr. Eugene Myers by Gail Fass

Betty Nelson and All Members of
SPOHNC by Gerald Maly

The Pepler Family by John Quealy

Edward & Marion Sadler by
Barm Alsbrook

Carole & George Saire by
Mr. & Mrs. Brindle

Garrett Smetano by
Margaret Minnick

Dr. Elliott Strong by Eileen Sini-Gormley

Ronald Willard by Emily Suyat

Cassandra E. Woods by Lewis Knight

Eat Well Stay Nourished
A Recipe and Resource Guide
for Coping With
Eating Challenges
compiled by
Nancy E. Leupold, Founder




\$20.00 includes shipping
and handling.

Eat Well Stay Nourished A Recipe
and Resource Guide for
Coping With Eating
Challenges - Volume 2
compiled by
Nancy E. Leupold,
Founder



\$23.00 includes shipping and handling.

Two Volume Set
LIMITED TIME
SPECIAL OFFER
\$25 PER SET -
A SAVINGS OF \$15!!



Order at spohnc.org or
contact SPOHNC at 1-800-377-0928

Make a Difference. Give a Gift Today.

***Nancy Leupold's Loving Page of Remembrance
2020***

Gifts Have Been Given In Memory Of

Rick Agee by John & Cynthia Agee,
Kerry & Janie Agee, Francey Beall,
Lynn Erickson, James Klein,
Joseph Lehmer, Randy Morgan,
Brad Neugent & Ross Helbing,
Steve Taber, Dave & Kelene Totzke,
Martha Trubey

Trisha A. Appelhans by
Daniel & Sharon Mouch

Harold Aptaker by Ruth Aptaker

Douglas Ballou by Nancy Anderson,
Kevin Asher, Kathryn Ballou,
Keith Brooks, Patrice Saurman

Madeleine Bendyna by
Lynne & Bruce Blatt

Maria Boland by Edward Boland

Richard Boucher by Dolores Boucher,
Margaret (Margie) Boucher,
Mary Ann Caputo, Glen Goto,
Lisa Gravelle, Amanda Hanlon,
Gary Lomayesva, Sara McNabb,
David Sours, Alexandra Whelan

Michael Bruce by Terry Bruce

Marge Budzenski by Amy Beilman,
Maureen Cullen

Jack Caskey by Donna Clarke

Jimmy Cerreta by Martha Hull,
Arlene Kruzal, Carl Kruzal

Mary Cordovano by Mary Ann Caputo

Daniel Coyle by Colleen Caterine

Avice W. Crock by Margaret Schoolar

Colleen Anne Davis by John Davis

Gerard "Gary" DeNapoli by
Elizabeth DeNapoli

Karen DeSimone by Denise DeSimone

Patricia Doherty by
Edward & Barbara Arienti

Jeffrey Erdos by Ronni Erdos

Vivian Rebecca Fishman by
Joanne Fishman

Maria Folchetti by Tom Folchetti

Bob Gedan by Winnie Gedan

**SPOHNC's Founder,
Nancy Leupold**
by
John & Cynthia Agee,
Susan Augusto,
Peter Baker, Robert Bishop,
Bruce & Lynne Blatt,
Kelly Bleach,
Walter & Irene Boehmler,
Robert Boisits, Margie Boucher,
Nanci Brody, Francesca Caputo,
Lawrence & Mary Ann Caputo,
Betty Cek, Joseph Dioguardi,
Annette Dippolito,
Eileen Dunnington, Gail Fass,
Donald Freed, Janet Fried,
Sandra Fuggini, Karen Galluzzi,
Charlotte Gyory, Denis Korjenek,
Walter Larkin, Linda Lehr,
Christiane Leonardis,
Robert Leupold,
Jack & Mary Ellen Mitchell,
Lynn Murphy, Claire Nelson,
Robin Pearl, Marilyn Prokesch,
Suzette Shih, Betty Slechts,
Theodore Stalzer, Dennis Staropoli,
Alice Steiner, Steven Stern,
Alan Swenson, Eric Swenson,
THANC Foundation, Marge Tidey,
Tom Walsh, Susan Weisberg,
Anne Wesp, Karen Wolk,
Chaplain Alan Wright

Fred Gerrick by Betty Cek

Patrick S. Gleason by Clare Baffoni,
Steven Bailey, Pamela Blumberg,
Gladys Gleason

Frank Gormley by Eileen Sini Gormley

Linda Graff by Gary Graff

Janet Greenspan by Lisa Lachs

Linda Hanlin by George Hanlin

Mary Haungs by Ben Kimbler

Art Hayes by Lewis & Amy Beilman

Sharon Kiefer by Richard Kiefer

Lorelei Kilbane by Joe Adams,
Carmen Brown, Bridget Doherty,
Jenna Gonzalez, Mary Kelley,
Judith Kostelansky, Terrence O'Brien,
Cynthia Pratt, Theodore Sauppe,
Kathleen Selig, Cathy Shemo,
Michael Tully

Bob Klauber by Alfred Tuckman

Jack Knetzger by Cathy Cassell,
Robert Knetzge, Barb Knoff,
William Mohr, James Ridley

Barry Landers by Lynne & Bruce Blatt

Frank Lear by William & Maureen Rogers

continued on next page

Do you have trouble
swallowing after cancer treatment?

FLEXITOUCH®
can help.



Learn more about our
at-home treatment at
tactilemedical.com/headandneck

**Tactile
MEDICAL®**
HEALING RIGHT AT HOME

continued from previous page

Ilene Levin by Steven Goldfine

Monica Susana Levine by Michael Levine

David Lopes by Beth Ferris

Paul E. Mashburn by Kathi Fjelstad

Robert McGeachie by Catherine McGeachie

Robert Michaels by Joan Griffith

Pradeep Narechania by Aditi Narechania

Sherri Neeler by Cynthia Hanks

Marjorie Nobles by Barbara Nobles

Jackie & Mel Nunnally by Kathryn Hull

Thomas Olsen by Johnny Stack

Joseph E. Parisi by Diane Parisi

Margarita Passione by Linda Vila Passione

George E. Perdew II by Natalie Perdew

Michael Phelps by Fay Phelps

Lillian Ritchie by Lynne & Bruce Blatt

Craig Ross by Kavita Amin,
Richard Cash, Theresa Duren,
Gary & Dale Morgenstern

Diane Rupert by Karen & Steve Rhoad,
Patrice Saurman, Estelle Young

Charles Santo by Dorothy Santo

Lou Scarpino by Alan Workinger

David Schultz by RoseAnne Pagac

Howard Starr by Jan Starr

Ronald Sturgeon by Harry August,
Paula & Linda Bowman,
Crestwood Association, Deborah Fearheller,
Gregory Korzen, Nick Masciantonio,
Mr. & Mrs. Potochnik, Paul Rominski

Patrick Szerletich by
Ron's Produce Co., Inc.

Karen E. Testa by Wendy Testa

William Wesp by Anne Wesp

Bob Wine by Ellen Hauptman, Louise Plate

WHY JOIN SPOHNC?? *The benefits of becoming a member...*

Right now, you're probably thinking... "but I am a member of SPOHNC! I get this newsletter a couple of times a year." Or maybe you're saying to yourself... "Oh, I'm already a member because I am part of a SPOHNC Chapter support group."

Did you know that you're receiving this issue of "News from SPOHNC" because you're part of a family of people that has been helped by SPOHNC?

If you have ever called us, e-mailed us or have ever been touched by SPOHNC in any way, we like to thank you, by sending you this complimentary April issue of "News from SPOHNC." In fact, you receive another one in October... but you are missing out on 6 additional issues, because you are not a member of SPOHNC.

SPOHNC members are already receiving the benefits listed here. If you haven't joined SPOHNC as a member, please consider doing so, and gain the "MEMBERS ONLY" benefits offered just for you. Membership is \$30 annually. If you're not already a member, you're missing out on some great resources that have been designed with care, to help

you. SPOHNC wants to provide you with all that you need. We are here to support you, because Together We Heal!

- Are you still dealing with side effects from your treatment? SPOHNC's 42 page PRODUCT DIRECTORY is here! Full of product suggestions and how they can help

you, the book also tells you where to find them. This book is a must for anyone who is seeking relief.

- "News from SPOHNC" Feature articles written by distinguished healthcare

professionals, sharing stories written by survivors, current head and neck cancer news, survivor and chapter news, human interest stories and more. Receive 8 issues per year.

- Access to SPOHNC's more than 100 Chapter Support groups.

- Access to SPOHNC's National Survivor Volunteer Network of more than 225 survivor and caregiver volunteers, ready and willing to serve as a mentor to a newly diagnosed patient or caregiver.

- Opportunities to connect with patients and survivors. Contact SPOHNC to find out how.

- Insider information about special programs and resources. You will be the first to know.

- Access to additional resources through direct contact with SPOHNC's Outreach Staff.



MEIRAGTx

AQUAx

Are you a cancer **SURVIVOR** suffering from dry mouth?

Learn more about participating in the AQUAx clinical research study.

www.aquaxstudy.com

CHAPTERS OF SPOHNC

Contact SPOHNC at 1-800-377-0928 for Chapter information & Facilitator contact information.

PLEASE NOTE: Chapters are not holding meetings in person at this time due to COVID-19.

Many groups have found other creative ways to support one another during this time of need.

Please call to SPOHNC to find out more information.

ALABAMA
BIRMINGHAM, MOBILE

ARIZONA
CHANDLER, GILBERT
PHOENIX (2), SCOTTSDALE

ARKANSAS
FAYETTEVILLE

CALIFORNIA
ARROYO GRANDE, LOS ANGELES
NEWPORT BEACH,
ORANGE-UCL,
SOUTH SAN FRANCISCO, SANTA MARIA,
STANFORD, VENTURA

COLORADO
DENVER

DC
GEORGETOWN

FLORIDA
DEERFIELD BEACH, FT MYERS,
JACKSONVILLE (2), NAPLES,
PALM COAST/NORTHEAST,
WINTER PARK

GEORGIA
ATLANTA, MACON,
SAVANNAH

IDAHO
MOSCOW

ILLINOIS
EVANSTON,
MAYWOOD, MORRIS, SPRINGFIELD

INDIANA
AVON
SOUTH BEND

IOWA
DES MOINES

KANSAS
KANSAS CITY

LOUISIANA
BATON ROUGE, NEW ORLEANS

MARYLAND
BALTIMORE-GBMC, BALTIMORE-JHMI,
LIBERTYTOWN

MASSACHUSETTS
BOSTON, CAPE COD, DANVERS

MICHIGAN
ANN ARBOR, SAGINAW, WARREN

MINNESOTA
MINNEAPOLIS, ST. PAUL

MISSOURI
ST. LOUIS/DPCC

MONTANA
MISSOULA

NEBRASKA
LINCOLN, OMAHA/MCC

NEW HAMPSHIRE
CONCORD

NEW JERSEY
CAMDEN, ENGLEWOOD,
LONG BRANCH, MORRISTOWN
PRINCETON/UMC

NEW YORK
BAY SHORE, BUFFALO,
MANHATTAN/BI, MANHATTAN, LH
MANHATTAN/MSDUS,
MANHATTAN/NYU, MIDDLETOWN,
NEW HYDE PARK,
ROCHESTER, SOUTHAMPTON,
STONY BROOK, SYOSSET, WHITE PLAINS,

NORTH CAROLINA
DURHAM

OHIO
DAYTON

OREGON
SOUTHERN OREGON

PENNSYLVANIA
DUNMORE,
HERSHEY, LANCASTER, LEBANON
PHILADELPHIA/UNIV. PENN HOSPITAL,
YORK

SOUTH CAROLINA
GREENVILLE (UPSTATE)

TENNESSEE
KNOXVILLE, NASHVILLE

TEXAS
DALLAS/BAYLOR
DALLAS/IRVING
SAN ANTONIO

UTAH
SALT LAKE CITY

VIRGINIA
CHARLOTTESVILLE, FAIRFAX,
NORFOLK, MECHANICSVILLE

WASHINGTON
KIRKLAND

WEST VIRGINIA
MORGANTOWN

WISCONSIN
APPLETON

*“SPOHNC is a wonderful
organization and worthy of
national note.”*

~ Mitch



SUPPORT FOR PEOPLE WITH
 ORAL AND HEAD AND NECK CANCER
 P. O. BOX 53
 LOCUST VALLEY, NY 11560-0053

NON-PROFIT
 ORGANIZATION
 U.S. POSTAGE
 PAID
 LOCUST VALLEY, NY
 PERMIT NO. 28

Give a Gift to SPOHNC
because...



Together We Heal

*For your convenience,
 your appeal envelope
 is enclosed*

to become a member and make a contribution by credit card or order online at www.spoync.org

Call 1-800-377-0928

- CONTRIBUTIONS**
- Leaders Circle, \$10,000+
 - Visionary Circle \$15,000+
 - Patron, \$500+
 - Benefactor, \$1,000+
 - Founder, \$5,000+
 - Booster, \$35+
 - Donor, \$50+
 - Sponsor, \$100+

- ANNUAL MEMBERSHIP**
- \$30.00
 - \$35.00 Foreign (US Currency)

First time member _____ Returning member _____

Please Check: Survivor _____ Friend _____ Health Professional (Specialty) _____

City _____ State _____ Zip _____

Address _____

Address _____ Email Address _____

Name _____ Phone (_____) _____

Membership includes subscription to eight issues of *News From SPOHNC & FREE Product Directory*

MEMBERSHIP APPLICATION
SUPPORT FOR PEOPLE WITH ORAL AND HEAD AND NECK CANCER, INC.
 P.O. Box 53, Locust Valley, NY 11560

SUPPORT FOR PEOPLE WITH ORAL AND HEAD AND NECK CANCER (SPOHNC)